Johnson&Johnson

Johnson & Johnson $JNJ (+2,53%) has achieved important goals in a phase 3 study with its drug for the treatment of skin diseases. The drug, an IL-23 inhibitor, showed a significant improvement in patients with moderate to severe psoriasis compared to placebo in the study. These results underline the therapy's potential to expand existing treatment options.

Further information can be found in the article on Reuters.

The news is based on what I personally consider to be reputable sources. However, I do not guarantee their accuracy. No advice.

I set up a custody account with Scalable Capital last week.

In addition to my cash flow depotwhich currently pays me a dividend of €709.45 next year (see picture), I will set up a savings plan custody account there.

This savings plan custody account will have a term of 20 years+.

I will pay in €495 per month and divide it between 15 companies as follows:

$GOOGL (-5,1%) - 33€

$AMZN (-1,75%) - 33€

$AAPL (+0,76%) -33€

$ASML (+2,27%) - 33€

$FAST (+1,11%) - 33€

$JNJ (+2,53%) - 33€

$MC (-1,56%) - 33€

$MCD (-0,68%) - 33€

$MSFT (-0,08%) - 33€

$NOVO B (-2,35%) - 33€

$PEP (+0,93%) - 33€

$PG (+1,81%) - 33€

$UNP (+2,39%) - 33€

$UNH (+0,05%) - 33€

$V (+1,33%) - 33€

The savings plans will be executed for the first time on Monday and then continue on a monthly basis.

I will post a monthly update here

In February 2024, I opened a securities account with Trade Republic and started saving 60 "stable" stocks from the S&5 500 per month with the aim of beating the S&P ETF in the long term. Since May, more than 30 additional stocks have been added and have proven to be an excellent decision so far. Among others $SFM (+1,81%)
$AMP (+2,57%)
$CMI (+2,94%)
$SNA (+1,41%)
$FI (+0,48%)
$PANW (+7,76%)
$ANET (+6,54%) .

There are now over 150 positions and not only 🇺🇸 shares (over 90%) in the portfolio but also a handful from 🇩🇪🇬🇧🇳🇱🇯🇵🇸🇬. They still have to prove their quality, but so far only 🇺🇸 stocks have delivered performance.

9 months since the start, my "ETF" can keep up quite well although the goal of beating the S&P500 has not yet been achieved. But I'm close and in July the gap was somewhat wider.

Conclusion: The popular dividend stocks have not provided performance in the portfolio as $JNJ (+2,53%)
$KO (+1,53%)
$PG (+1,81%)
$PEP (+0,93%) The popular growth stocks from the semiconductor sector have not yet been able to prove their quality either. $ASML (+2,27%)
$SNPS (+3,74%)
$KLAC (+3,55%)
$LRCX (+4,74%)
$AMAT (+4,1%) The healthcare sector has also been somewhat disappointing. $ISRG (+1,83%) and $SYK (+1,97%) are positive exceptions here.

The usual suspects, on the other hand, have performed very well, although Microsoft is lagging a little behind. Otherwise, the financial sector and almost all stocks in the industrial sector have performed well so far.

Let's see how things continue to develop.😁

$JNJ (+2,53%)

What do you think of the UN?

I don't think a price/cash flow of 15.5 is expensive, but there's probably not much room for multiple expansion. According to the UN, the target is 5-7% annual growth until 2030. Add to that around 3% dividend.

I.e. the UN would yield 8-10% per year (assuming the valuation remains the same). I'm considering whether the individual share risk pays off if the profit expectation is in the range of the MSCI World 😅

Hello everyone,

some of your contributions have motivated me to share something.

Briefly about me: I am 30 years old, employed and have a net income of approx. 3600€ (approx. 4000€ at the beginning of 2025). Quite a new father, so I'm curious to see how I can still maintain and increase my savings goals.

I had to more or less liquidate my savings account in 2021 due to a house purchase, otherwise I would probably already be a bit further ahead.

I'm currently saving €415 a month via savings plans and I also make one-off purchases when it suits me financially.

My portfolio is not yet clear enough for my taste. My goal is the following allocation:

60% ETF

20% individual shares

10% gold

10% P2P

Uniglobal is currently still quite strongly represented. This is a VWL legacy, as my bank advisor recommended it to me at the time. I haven't changed it yet as I had other focal points. But I'm aiming to do that. But I'm not yet sure what exactly I'm saving for.

My goal for the coming months and 1-2 years:

To $IWDA (+1,13%) to ensure that the shares are redistributed automatically. I will leave P2P. I will buy gold as soon as I have cracked the 20k mark (as a reward, so to speak). I will also leave the individual shares I have. In some cases, I also save these via a savings plan ($KTN (-1,71%)
$KO (+1,53%)
$SHEL (+1,48%) and $JNJ (+2,53%) )

In 2 weeks I would like to invest about 1.5k of my Christmas money. Here, too, I am currently leaning towards $IWDA (+1,13%) .

Overall, I'm trying to increase my savings rate, but I'll have to wait and see how this is possible due to my new role as a father. My mother is on parental leave and receives parental allowance.

What would you change in my portfolio if it were yours? I am grateful for any advice and look forward to your comments.

Your Dominik

I tidied up my portfolio a bit today. This has partly to do with the fact that I think the stock market is currently running a bit hot, but it's not the decisive factor; it's simply a time when it seems wise to sell some stocks that were no longer at the top of my want list anyway.

First of all, some of you may have noticed that I have switched most of the growth portfolio to ETFs. I've also tidied up a bit there, but it's not worth mentioning.

In the dividend portfolio, I shifted a little more back and forth; although initially I only shifted to the cash portfolio and not yet shifted :D Some of you may remember that I took over some of my grandparents' shares, some of which are also old tax holdings. This is also the case here. But there's no doubt that I also had to pay a lot of tax on the non-old stock. However, I also wanted to tidy up a bit, even though the dividend portfolio was actually intended for buy and hold (forever), so sometimes it turns out that you should perhaps sell after all.

$SBUX (+2,05%) I had started to build up a position at around 85. Then came the Starbucks "crash". This forced me to buy some more. However, the position has become far too large for my dividend portfolio, so I reduced it by a little more than 1/2.

$SAP (+0,97%)
@Karl_ <- Following on from Karl's post. I have a similar view and think that the valuation is no longer really justified. I am also unsure about the German market as a whole at the moment. But after all, SAP also does a lot of business in America. 100% out

$JPM (+2,36%) Perhaps a controversial decision. But I'm not entirely convinced by JPM's return on capital, even for a bank. It is certainly a good investment, but not for me at the moment. But that's more of a gut decision. 100% out

$DHL (-1,01%)
$7974 (+1,22%) were mini positions. Question: Continue to build up or get out? The latter was the answer. I don't see an absolute reason to buy at the moment. 100% liquidated

$JNJ (+2,53%) certainly also a controversial decision. However, I am not convinced by either the performance or the fundamentals. 100% out.

$AZN (+1,31%) Bought Corona for a good reason (vaccination). Now took profits. 100% out.

That's it for now. I now have a cash ratio of almost 50%, which is of course far too much. The cash will flow partly into ETFs in the former growth portfolio and partly into dividend stocks. The main focus will be on consumer staples, industrials and healthcare - if better opportunities arise there. I will gradually build up positions there and post my reasons accordingly.

Edit: I am always grateful for ideas in consumer staples/industrials/healthcare + dividend paying.

Is regrouped in $WELS (+0,92%)

J&J -Q3 2024

The results of $JNJ (+2,53%) for the third quarter of 2024 reflect a solid performance across all business segments, supported by strategic progress and operational growth. The company reported global sales of 22.5 billion US dollarswhich represents an increase of 5,2 % compared to the previous year, with operating growth of 6,3 % amounted to 6.3%. The US market in particular recorded strong growth with an increase in sales of 7,6 %.

In terms of profit, diluted earnings per share fell by 34,3 % to 1.11 US dollarswhile adjusted diluted earnings per share fell by 9,0 % to 2.42 US dollars fell. This decline was largely due to expenses for acquired research and development projects (IPR&D), which which reduced the result by around 1,900 basis points burdened the result.

In the Innovative Medicine-segment generated sales of 14.6 billion US dollars were achieved, an increase of 4,9 % or operationally by 6,3 %. The main growth drivers included the strong results of DARZALEX, CARVYKTI and ERLEADAwith sales at DARZALEX increasing by 20,7 % increased.

The MedTech-segment also showed solid growth, with a global increase in sales of 5,8 % and operationally by 6,4 %supported by innovations in electrophysiology and the successful market launches of new products such as the VELYS Spine and the Shockwave E8 IVL catheter.

Strategically, Johnson & Johnson made important progress in its product pipeline, including approvals for TREMFYA and RYBREVANTas well as submissions for new therapies in various areas of application. In addition, the acquisition of V-Wave was completed, which should further strengthen the company's position in the field of cardiovascular medicine.

Looking to the future, Johnson & Johnson has revised its forecast for 2024 and expects adjusted operating sales growth of between 5.7% and 5.7% and 6.2% and adjusted operating earnings per share between 9.86 and 9.96 US dollars. The company remains focused on leveraging its extensive healthcare capabilities to drive long-term growth and innovation.

I have maintained my position in the stock and hope that the Medtech division will be floated soon. Even if that doesn't happen, I still see it as a great stock.